Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2013 Financial Results
Date:11/5/2013

DUBLIN, Nov. 5, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2013 and updated 2013 financial guidance.

"We continued to deliver strong growth and profitability during the third quarter while further strengthening our cash position," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "With disciplined investments and successful execution of our corporate growth strategy, we believe we are well positioned to continue to generate significant growth and shareholder value."

Adjusted net income for the third quarter of 2013 was $109.4 million, or $1.78 per diluted share, compared to $78.6 million, or $1.29 per diluted share, for the third quarter of 2012.

GAAP net income for the third quarter of 2013 was $75.4 million, or $1.23 per diluted share. GAAP income from continuing operations for the third quarter of 2012 was $33.6 million, or $0.56 per diluted share, and GAAP net income for the third quarter of 2012 was $33.2 million, or $0.55 per diluted share. GAAP net income for the third quarter of 2012 included GAAP loss from discontinued operations of $0.4 million, or $0.01 per diluted share.

Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included in this press release.

Third Quarter 2013 Revenues and Product SalesTotal revenues for the third quarter of 2013 were $232.2 million, compared to total revenues of $175.5 million for the third quarter of 2012. This increase was driven primarily by increased net sales of Xyrem and Erwinaze. Total revenues include net sales, royalties and contract revenues.

Tables showing net sales for the three and nine months ended September 30, 2013 compared to actual and pro forma net sales for the same periods in 2012 are included in this press release.

Net sales for the third quarter of 2013 were as follows:

  • Xyrem® (sodium oxybate) oral solution: Xyrem net sales increased by 50% to $153.7 million in the third quarter of 2013 compared to $102.6 million in the third quarter of 2012. During the third quarter of 2013, the average number of active Xyrem patients was approximately 11,000.
  • Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi): Erwinaze/ Erwinase worldwide net sales increased by 39% to $44.1 million in the third quarter of 2013 compared to $31.7 million in the third quarter of 2012.
  • Prialt® (ziconotide) intrathecal infusion: Net sales of Prialt were $11.0 million in the third quarter of 2013 compared to net sales of $5.4 million for the same period of 2012. During the third quarter of 2013, net sales included a $5.7 million sale to Eisai Co., the European distributor of Prialt. During 2012, the sale to Eisai occurred during the three months ended March 31, 2012.
  • Psychiatry Products: Net sales of the company's psychiatry products were $10.7 million in the third quarter of 2013 compared to net sales of $21.0 million for the same period of 2012. This decrease was primarily due to the impact of generic competition.
  • Other: Net sales of other products for the third quarter of 2013 were $10.9 million compared to net sales of $13.4 million in the same period of 2012.
  • Operating Expenses and Other Operating expenses for the third quarter of 2013 were $131.6 million compared to $120.2 million for the third quarter of 2012. Operating expenses changed over the prior year period for the following reasons:

  • Cost of product sales for the third quarter of 2013 was $24.3 million compared to $32.6 million for the same period in 2012. The decrease in the 2013 period was primarily due to a decrease in acquisition accounting inventory fair value step-up adjustments of $9.8 million. Gross margin for the third quarter of 2013, as a percentage of product sales, was 89.5% compared to 81.3% for the same period in 2012.
  • Selling, general and administrative ("SG&A") and research and development ("R&D") expenses for the third quarter of 2013 totaled $87.8 million on a GAAP basis compared to $67.8 million for the same period of 2012. The increase reflected higher headcount and related expenses due to the expansion of the business and an increase in the fair value of contingent consideration related to the acquisition of EUSA Pharma in June 2012, partially offset by lower transaction and integration costs. Adjusted combined SG&A and R&D expenses for the third quarter of 2013 totaled $69.5 million compared to $57.9 million for the same period in 2012.
  • Net interest expense in the third quarter of 2013 was $6.2 million. As of September 30, 2013, cash and cash equivalents were $588.5 million, and the balance of the company's term loans was $551.1 million. Cash and cash equivalents increased from December 31, 2012 primarily due to the cash generated from the business and the net proceeds of term loans that were refinanced in June 2013, offset in part by funds used by the company to repurchase its ordinary shares under the company's share repurchase program and increases in working capital.

    In May 2013, the board of directors authorized the use of up to $200 million to repurchase the company's ordinary shares. In the third quarter of 2013, the company repurchased 0.6 million shares for $48.8 million at an average cost of $80.91 per share. As of September 30, 2013, a total of 1.4 million shares had been repurchased for $102.4 million at an average cost of $70.64 per share.

    During the fourth quarter of 2012, the company sold its women's health business. Financial results from the women's health business are reported as discontinued operations for the 2012 periods. 2013 Financial Guidance Jazz Pharmaceuticals is providing the following updated 2013 guidance:Revenues

    $867-$877 millionTotal Net Product Sales

    $860-$870 million-Xyrem Net Sales

    $565-$570 million-Erwinaze/Erwinase Net Sales

    $173-$178 millionAdjusted Gross Margin %1,3

    88-90%Adjusted Combined SG&A and R&D Expenses2,3

    $275-$280 millionGAAP Net Income Per Diluted Share

    $3.63-$3.79Adjusted Net Income Per Diluted Share3

    $6.30-$6.401.

    Excludes $4 million of acquisition accounting inventory fair value step-up adjustments and $3 million in share-based compensation expense from estimated GAAP gross margin of 87-89%.2.

    Excludes $42 million of share-based compensation expense, $15 million related to a change in fair value of contingent consideration, $3 million of depreciation expense, $5 million of upfront license fees and $3 million of transaction, integration and restructuring costs from estimated GAAP combined SG&A and R&D expenses of $343-$348 million.3.

    See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the tables accompanying this press release.Conference Call DetailsJazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EST (9:30 p.m. GMT) to provide a business update and discuss its third quarter 2013 results and updated 2013 financial guidance. The live webcast may be accessed from the Investors & Media section of the company's website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing +1 800 591 6942 in the U.S., or +1 617 614 4909 outside the U.S., and entering passcode 48257479.

    A replay of the conference call will be available through November 12, 2013 by dialing +1 888 286 8010 in the U.S., or +1 617 801 6888 outside the U.S., and entering passcode 18933289.

    An archived version of the webcast will be available for at least one week in the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  

    About Jazz PharmaceuticalsJazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com.

    Non-GAAP Financial MeasuresTo supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the company uses certain non-GAAP (also referred to as "adjusted" or "non-GAAP adjusted") financial measures in this press release and the accompanying tables. The company believes that each of these non-GAAP financial measures is helpful in understanding its past financial performance and potential future results, particularly in light of the effect of various acquisition and divestiture transactions effected by the company during 2012. They are not meant to be considered in isolation or as a substitute for comparable GAAP measures, and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP. Jazz Pharmaceuticals' management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate its business and make operating decisions. Compensation of executives is based in part on the performance of the company's business based on certain of these non-GAAP financial measures. In addition, Jazz Pharmaceuticals believes that the presentation of these non-GAAP financial measures is useful to investors because it enhances the ability of investors to compare its results from period to period and allows for greater transparency with respect to key financial metrics the company uses in making operating decisions, and also because the company's investors and analysts regularly use them to model and track the company's financial performance.

    Investors should note that these non-GAAP financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Because of the non-standardized definitions, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the company's competitors and other companies.

    As used in this press release, (i) the historical adjusted net income measures exclude from GAAP income from continuing operations, as applicable, amortization of intangible assets, share-based compensation expense, acquisition accounting inventory fair value step-up adjustments, transaction and integration costs, restructuring charges, change in fair value of contingent consideration, upfront license fees, depreciation expense, loss on extinguishment and modification of debt and other non-cash expense, and adjust the income tax provision to the estimated amount of taxes that are payable in cash; (ii) the historical adjusted combined SG&A and R&D expenses exclude from GAAP combined SG&A and R&D expenses, as applicable, share-based compensation expense, change in fair value of contingent consideration, transaction and integration costs, restructuring charges, depreciation expense and upfront license fees; (iii) the adjusted net income guidance measures exclude from estimated GAAP net income amortization of intangible assets and depreciation expense, share-based compensation expense, acquisition accounting inventory fair value step-up adjustments, transaction, integration and restructuring costs, change in fair value of contingent consideration, upfront license fees, loss on extinguishment and modification of debt and other non-cash expense, and adjust the income tax provision to the estimated amount of taxes that are payable in cash; (iv) the adjusted gross margin percentage guidance excludes from estimated GAAP gross margin percentage acquisition accounting inventory fair value step-up adjustments and share-based compensation expense; and (v) the adjusted combined SG&A and R&D expenses guidance excludes from estimated GAAP combined SG&A and R&D expenses share-based compensation expense, change in fair value of contingent consideration, depreciation expense, upfront license fees and transaction, integration and restructuring costs.

    "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial results, the company's growth strategy and potential, 2013 financial guidance and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining and increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition and changed or increased regulatory restrictions on or requirements with respect to Xyrem, as well as similar risks related to effectively commercializing the company's other marketed products, including Erwinaze and Prialt; protecting and expanding the company's intellectual property rights; obtaining appropriate pricing and reimbursement for the company's products in an increasingly challenging environment; ongoing regulation and oversight by U.S. and non-U.S. regulatory agencies; dependence on key customers and sole source suppliers, including the risk that the company may not be able to supply sufficient product to meet demand; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof and the uncertainty of clinical success and regulatory approval; the company's ability to identify and acquire, in-license or develop additional products or product candidates to grow its business; and possible restrictions on the company's ability and flexibility to pursue certain future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results; and those other risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 and future filings and reports by the company. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

     

     

    JAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share amounts)(Unaudited) Three Months Ended
    September 30,Nine Months Ended
    September 30,2013201220132012Revenues:Product sales, net

    $

    230,386$

    174,130$

    631,602$

    398,585Royalties and contract revenues

    1,7741,3855,0473,691Total revenues

    232,160175,515636,649402,276Operating expenses:Cost of product sales

    24,25232,62976,50352,662Selling, general and administrative

    74,97060,924223,004162,505Research and development

    12,8146,92032,81113,200Intangible asset amortization

    19,56419,74258,51843,444Total operating expenses

    131,600120,215390,836271,811Income from operations

    100,56055,300245,813130,465Interest expense, net

    (6,202)(7,750)(20,743)(9,199)Foreign currency loss

    (614)(1,099)(728)(1,357)Loss on extinguishment and modification of debt

    ——(3,749)—Income from continuing operations before income tax provision

    93,74446,451220,593119,909Income tax provision

    18,33512,85659,57424,966Income from continuing operations

    75,40933,595161,01994,943Loss from discontinued operations

    —(386)—(6,908)Net income

    $

    75,409$

    33,209$

    161,019$

    88,035Basic income (loss) per ordinary share:Income from continuing operations

    $

    1.30$

    0.59$

    2.76$

    1.69Loss from discontinued operations

    —(0.01)—(0.12)Net income

    $

    1.30$

    0.58$

    2.76$

    1.57Diluted income (loss) per ordinary share:Income from continuing operations

    $

    1.23$

    0.56$

    2.62$

    1.59Loss from discontinued operations

    —(0.01)—(0.12)Net income

    $

    1.23$

    0.55$

    2.62$

    1.47Weighted-average number of ordinary shares outstanding:Basic

    58,21757,70358,43756,198Diluted

    61,51960,88361,53259,846 JAZZ PHARMACEUTICALS PLCSUMMARY OF PRODUCT SALES, NET(In thousands)(Unaudited)Three Months Ended
    September 30,Nine Months Ended
    September 30,2013201220132012Xyrem

    $

    153,664$

    102,615$

    404,932$

    265,149Erwinaze/Erwinase

    44,07831,652130,75437,660Prialt

    11,0465,41320,72620,491Psychiatry

    10,67921,03240,09358,518Other

    10,91913,41835,09716,767Total

    $

    230,386$

    174,130$

    631,602$

    398,585The following compares actual net product sales for the three and nine months ended September 30, 2013 to unaudited pro forma information representing combined net product sales for the three and nine months ended September 30, 2012, as if the merger with Azur Pharma, the acquisition of EUSA Pharma and the disposition of the women's health business had each been completed on January 1, 2012:SUMMARY OF PRODUCT SALES, NET (PRO FORMA)(In thousands)(Unaudited)Three Months Ended
    September 30,Nine Months Ended
    September 30,2013201220132012Xyrem

    $

    153,664$

    102,615$

    404,932$

    265,149Erwinaze/Erwinase

    44,07831,652130,75497,447Prialt

    11,0465,41320,72620,830Psychiatry

    10,67921,03240,09358,881Other

    10,91913,41835,09738,708Total pro forma net sales

    $

    230,386$

    174,130$

    631,602$

    481,015 JAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)September 30,
    2013December 31,
    2012ASSETSCurrent assets:Cash and cash equivalents

    $

    588,462$

    387,196Accounts receivable, net

    113,27175,480Inventories

    24,86826,525Prepaid expenses

    19,3507,445Deferred tax assets, net

    45,56535,813Other current assets

    18,55119,113Total current assets

    810,067551,572Property and equipment, net

    12,0607,281Intangible assets, net

    823,724869,952Goodwill

    446,823442,600Deferred tax assets, net, non-current

    70,97674,850Deferred financing costs

    15,45816,576Other non-current assets

    6,3913,662Total assets

    $

    2,185,499$

    1,966,493LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable

    $

    22,434$

    15,887Accrued liabilities

    106,390104,666Current portion of long-term debt

    5,57229,688Income taxes payable

    19,85039,884Contingent consideration

    47,700—Deferred tax liability, net

    275275Deferred revenue

    1,1381,138Total current liabilities

    203,359191,538Deferred revenue, non-current

    6,0016,776Long-term debt, less current portion

    545,564427,073Contingent consideration, non-current

    —34,800Deferred tax liability, net, non-current

    170,127178,393Other non-current liabilities

    16,7476,621Total shareholders' equity

    1,243,7011,121,292Total liabilities and shareholders' equity

    $

    2,185,499$

    1,966,493 JAZZ PHARMACEUTICALS PLCRECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION(In thousands, except per share amounts)(Unaudited)Three Months Ended
    September 30,Nine Months Ended September 30,2013201220132012GAAP reported income from continuing operations

    $

    75,409$

    33,595$

    161,019$

    94,943Intangible asset amortization

    19,56419,74258,51843,444Share-based compensation expense

    11,8766,35532,13914,684Acquisition accounting inventory fair value step-up

    51210,3363,14314,676Transaction and integration costs

    1131,5031,84617,692Restructuring charges

    —1,6331,4572,180Change in fair value of contingent consideration

    5,00090012,9001,100Upfront license fees

    988—4,988—Depreciation

    895—2,065—Loss on extinguishment and modification of debt

    ——3,749—Other non-cash expense

    1,0831,2613,5051,569Income tax adjustments

    (6,043)3,263(3,198)6,160Non-GAAP adjusted net income

    $

    109,397$

    78,588$

    282,131$

    196,448GAAP reported income from continuing operations per diluted share

    $

    1.23$

    0.56$

    2.62$

    1.59Non-GAAP adjusted net income per diluted share

    $

    1.78$

    1.29$

    4.59$

    3.28Shares used in computing GAAP reported income from continuing operations and non-GAAP adjusted net income per diluted share amounts

    61,51960,88361,53259,846JAZZ PHARMACEUTICALS PLCRECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATIONCERTAIN LINE ITEMS AND OTHER INFORMATION(In thousands, except per share amounts and percentages)(Unaudited)Three Months EndedSeptember 30, 2013September 30, 2012GAAP ReportedAdjustmentsNon-GAAP Adjusted *GAAP ReportedAdjustmentsNon-GAAP Adjusted *Total revenues$232,160$

    —$

    232,160$175,515$

    —$

    175,515Cost of product sales 24,252(1,103)

    (a)

    23,14932,629(10,771)

    (a)

    21,858Selling, general and administrative74,970(15,345)

    (b)

    59,62560,924(9,275)

    (b)

    51,649Research and development12,814(2,936)

    (c)

    9,8786,920(681)

    (c)

    6,239Intangible asset amortization19,564(19,564)—19,742(19,742)—Interest expense, net6,202(1,083)

    (d)

    5,1197,750(1,261)

    (d)

    6,489Foreign currency loss614—6141,099—1,099Income from continuing operations before income tax provision93,74440,031

    (e)

    133,77546,45141,730

    (e)

    88,181Income tax provision18,3356,043

    (f)

    24,37812,856(3,263)

    (f)

    9,593Effective tax rate (g)

    19.6%18.2%27.7%10.9%Income from continuing operations $75,409$

    33,988

    (h)

    $

    109,397$33,595$

    44,993

    (h)

    $

    78,588Income from continuing operations per diluted share$1.23$

    1.78$0.56$

    1.29 Nine Months EndedSeptember 30, 2013September 30, 2012GAAP ReportedAdjustmentsNon-GAAP Adjusted *GAAP ReportedAdjustmentsNon-GAAP Adjusted *Total revenues$636,649$

    —$

    636,649$402,276$

    —$

    402,276Cost of product sales 76,503(5,032)

    (i)

    71,47152,662(15,766)

    (i)

    36,896Selling, general and administrative223,004(43,953)

    (j)

    179,051162,505(32,848)

    (j)

    129,657Research and development32,811(9,553)

    (k)

    23,25813,200(1,718)

    (k)

    11,482Intangible asset amortization58,518(58,518)—43,444(43,444)—Interest expense, net20,743(3,505)

    (l)

    17,2389,199(1,569)

    (l)

    7,630Foreign currency loss728—7281,357—1,357Loss on extinguishment and modification of debt3,749(3,749)————Income from continuing operations before income tax provision220,593124,310

    (m)

    344,903119,90995,345

    (m)

    215,254Income tax provision59,5743,198

    (n)

    62,77224,966(6,160)

    (n)

    18,806Effective tax rate (g)

    27.0%18.2%20.8%8.7%Income from continuing operations $161,019$

    121,112

    (o)

    $

    282,131$94,943$

    101,505

    (o)

    $

    196,448Income from continuing operations per diluted share$2.62$

    4.59$1.59$

    3.28 

    JAZZ PHARMACEUTICALS PLCRECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATIONCERTAIN LINE ITEMS AND OTHER INFORMATION(In thousands, except per share amounts and percentages)(Unaudited) *

    Non-GAAP adjusted net income and its line item components and related non-GAAP adjusted financial measures, including non-GAAP adjusted effective tax rate, shown in the tables above are not meant to be considered in isolation or as a substitute for comparable GAAP reported measures, and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP. The company believes that each of these non-GAAP adjusted financial measures is helpful in understanding its past financial performance and potential future results, particularly in light of the effect of various acquisition and divestiture transactions effected by the company during 2012. In addition, the company believes that the presentation of these non-GAAP adjusted financial measures is useful to investors because it enhances the ability of investors to compare its results from period to period and allows for greater transparency with respect to key financial metrics the company uses in making operating decisions, and also because the company's investors and analysts regularly use them to model and track the company's financial performance. Specifically, the company believes that each of these non-GAAP adjusted financial measures provides useful information to management, investors and analysts by excluding certain expenses, such as acquisition-related and restructuring costs, share-based compensation, amortization of intangible assets, depreciation and other non-cash expense, as well as by excluding acquisition accounting inventory fair value step-up adjustments from cost of goods sold, upfront license fees, loss on extinguishment and modification of debt and related income tax adjustments, as the case may be, that may not be indicative of the company's core operating results and business outlook. Investors should note that these non-GAAP adjusted financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP adjusted financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP adjusted financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP adjusted financial measures. Because of the non-standardized definitions, the non-GAAP adjusted financial measures appearing in the tables above may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the company's competitors and other companies.Explanation of Adjustments and Certain Line Items:(a)

    Share-based compensation expense of $591 and $344, acquisition accounting inventory fair value step-up adjustments of $512 and $10,336, and restructuring charges of $0 and $91 for the three months ended September 30, 2013 and 2012, respectively. (b)

    Share-based compensation expense of $9,354 and $5,330, change in fair value of contingent consideration of $5,000 and $900, depreciation expense of $878 and $0, transaction and integration costs of $113 and $1,503, and restructuring charges of $0 and $1,542 for the three months ended September 30, 2013 and 2012, respectively. (c)

    Share-based compensation expense of $1,931 and $681, upfront license fees of $988 and $0, and depreciation expense of $17 and $0 for the three months ended September 30, 2013 and 2012, respectively. (d)

    Non-cash interest expense associated with debt discount and debt issuance costs for the three months ended September 30, 2013. Non-cash interest expense associated with debt discount and debt issuance costs and amortization of product rights liability for the three months ended September 30, 2012.(e)

    Sum of adjustments (a) through (d) plus the adjustment for intangible asset amortization for the respective three month period.(f)

    Adjustments to convert the income tax provision to the estimated amount of taxes payable in cash for the three months ended September 30, 2013. Tax related to acquisition restructuring of $9,529, partially offset by an adjustment of $6,266 to convert the income tax provision to the estimated amount of taxes payable in cash for the three months ended September 30, 2012.(g)

    Income tax provision divided by income from continuing operations before income tax provision.(h)

    Net of adjustments (e) and (f) for the respective three month period.(i)

    Acquisition accounting inventory fair value step-up adjustments of $3,143 and $14,676, share-based compensation expense of $1,788 and $999, restructuring charges of $68 and $91, and transaction and integration costs of $33 and $0 for the nine months ended September 30, 2013 and 2012, respectively. (j)

    Share-based compensation expense of $25,898 and $11,967, change in fair value of contingent consideration of $12,900 and $1,100, depreciation expense of $2,008 and $0, transaction and integration costs of $1,758 and $17,692, and restructuring charges of $1,389 and $2,089 for the nine months ended September 30, 2013 and 2012, respectively. (k)

    Upfront license fees of $4,988 and $0, share-based compensation expense of $4,453 and $1,718, depreciation expense of $57 and $0, and transaction and integration costs of $55 and $0 for the nine months ended September 30, 2013 and 2012, respectively. (l)

    Non-cash interest expense associated with debt discount and debt issuance costs for the nine months ended September 30, 2013. Non-cash interest expense associated with debt discount and debt issuance costs and amortization of product rights liability for the nine months ended September 30, 2012.(m)

    Sum of adjustments (i) through (l) plus the adjustments for intangible asset amortization and, as applicable, loss on extinguishment and modification of debt, for the respective nine month period.(n)

    Adjustments to convert the income tax provision to the estimated amount of taxes payable in cash for the nine months ended September 30, 2013. Tax related to acquisition restructuring of $15,379 partially offset by an adjustment of $9,219 to convert the income tax provision to the estimated amount of taxes payable in cash for the nine months ended September 30, 2012.(o)

    Net of adjustments (m) and (n) for the respective nine month period. JAZZ PHARMACEUTICALS PLCRECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2013 GUIDANCE(In millions, except per share amounts)(Unaudited)GAAP net income

    $223 - $233Intangible asset amortization and depreciation

    81Share-based compensation expense

    45Acquisition accounting inventory fair value step-up

    4Transaction, integration and restructuring costs

    3Change in fair value of contingent consideration

    15Upfront license fees

    5Loss on extinguishment and modification of debt

    4Other non-cash expense

    5Income tax adjustments

    (2) - 2Non-GAAP adjusted net income

    $387 - $393GAAP net income per diluted share

    $3.63 - $3.79Non-GAAP adjusted net income per diluted share

    $6.30 - $6.40Shares used in computing GAAP and non-GAAP adjusted net income per diluted share amounts

    61 


    '/>"/>
    SOURCE Jazz Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
    2. Aquavit Pharmaceuticals Adds New Advanced Drug Delivery Technology to Product Portfolio
    3. Jazz Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference on November 12
    4. Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
    5. Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
    6. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
    7. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
    8. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
    9. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
    10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
    11. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/4/2016)... Feb. 4, 2016 Wegener Polyangiitis - ... Markets Direct,s, ,Wegener Polyangiitis - Pipeline Review, H2 ... therapeutic pipeline. This report provides comprehensive information ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ...
    (Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
    (Date:2/4/2016)... 4, 2016 In response to the opioid abuse ... Commissioner for Medical Products and Tobacco, along with other FDA ... agency,s approach to opioid medications. The plan will focus on ... in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure that ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... After ... Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to ... Scarborough Hospital. He successfully completed his first three-year term as chief and began a ...
    (Date:2/5/2016)... , ... February 05, 2016 , ... The American public ... such water may be safer than regular municipal or well water. The recent experience ... host Sharon Kleyne, could go a long way toward increasing public acceptance of recycled ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Pivot ... 2015 Best in KLAS: Software & Services for HIT Implementation Support & Staffing ... report independently ranks vendor performance by healthcare executives, managers and clinicians representing over ...
    (Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
    (Date:2/5/2016)... ... February 05, 2016 , ... California Mobile Kitchens ... debut of their latest mobile kitchen model, featuring customizable stainless steel interiors and ... commercial kitchens for use anywhere in the U.S. Many of their units can ...
    Breaking Medicine News(10 mins):